ReviewCurrent pharmaceutical design2025
The Role of MicroRNAs, CircRNAs, and LncRNAs in Chronic Lymphocytic Leukemia.
Review in Current pharmaceutical design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Investigating autophagy and miRNAs as therapeutic targets in leukemia.Discover oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Chronic lymphocytic leukemia (CLL) constitutes a heterogeneous hematological malignancy, often correlated with disruptions in various signaling pathways, chromosomal deletions, and gene mutations. A comprehensive grasp of CLL pathogenesis and its associated risk factors remains vital for the development of more efficacious treatment strategies. Although non-coding RNAs (ncRNAs) do not encode proteins, they possess substantial regulatory influence over target genes. These ncRNAs govern a multitude of target genes implicated in the pathogenesis of CLL. Furthermore, some ncRNAs serve as prognostic markers in CLL and might contribute to overcoming chemotherapy resistance. This review determines the association between ncRNAs and the molecular mechanisms driving the onset and advancement of CLL, with particular emphasis on the roles of these ncRNAs in modulating signaling pathways, encompassing NF-κB/PI3K-AKT/TNF and P53 in CLL. It also underscores their relevance as significant biomarkers and their potential as therapeutic targets in clinical CLL settings.
Indexed as
Identifiers
40289974What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.